Téarnamh & Deisiú.
An tseilf dheisiúcháin: BPC-157, TB-500, an dá cheann acu i bpeann amháin, chomh maith le KPV, ARA-290, cartalax agus thymalin. Léigh na leathanaigh fianaise sula n-ordaíonn tú — tá an litríocht ar ainmhithe substaintiúil anseo agus tá an litríocht dhaonna tanaí, agus baineann an dá fhíric leis an leathanach céanna.
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%Sula n-ordaíonn tú
BioregulatorsCartalax and Chonluten: the bioregulators with almost no published record
Same Khavinson school as Thymalin and Epithalon, a fraction of the evidence. One cell-culture study for Chonluten, no readable efficacy study at all for Cartalax — and that asymmetry is the article.
LongevityEpithalon and the telomere claim: what the Khavinson papers actually report
Telomerase reactivation in a dish, extra passages past the Hayflick limit, longer-lived flies and mice — and no modern human trial. The published Epithalon record, figure by figure.
RepairARA-290 (cibinetide): four human trials, and the endpoints they missed
This is one of the very few compounds on the repair shelf with real randomised human data — four published trials, including a 64-subject phase 2b. Read them closely and the nerve-regeneration endpoint separates from placebo while the pain endpoint mostly does not.